Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854469 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10426876 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10426895 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10426894 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10426877 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10426928 | 0.85 | CHRNB2 (0.48) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10426927 | 0.85 | CHRNB2 (0.48) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10344362 | 0.84 | CRHBP (0.43) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL10344360 | 0.84 | CRHBP (0.43) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA | |
| SCHEMBL3345807 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1L3MBTL1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0445987-A2 | Novel process for producing 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate-3-methyl ester-5-beta-(N-benzyl-N-methylamino)ethyl ester | HIGASHIKAWA, Tetsuro (JP) | 1991-09-11 | — | — | EP | claimed |
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | NAVINTA LLC. | 2008-05-29 | — | — | US | disclosed |
| US-5508406-A | FOR TREATING CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-16 | — | — | US | disclosed |
| EP-0462696-B1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMA CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0270926-B1 | AGENTS PROMOTING THE ACTIVITY OF SOME ANTITUMOR AGENTS AND METHODS FOR THEIR PRODUCTION | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0159040-B1 | PYRIDINE DERIVATIVES AND PRODUCTION THEREOF | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0462696-A1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-12-27 | — | — | EP | disclosed |
| US-5075440-A | Hypotensive, bronchodilator agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0121117-B1 | DERIVATIVES OF DIHYDROPYRIDINE AND PRODUCTION THEREOF | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0270926-A2 | Agents promoting the activity of some antitumor agents and methods for their production | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1988-06-15 | — | — | EP | disclosed |
| EP-0245680-A2 | A process for the preparation of 2-(N-benzyl-N-methylamino)-ethyl-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate hydrochloride | ISTITUTO LUSO FARMACO D'ITALIA S.p.A. (IT) | 1987-11-19 | — | — | EP | disclosed |
| US-4579859-A | HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
| US-4578395-A | Certain aralkylaminoalkyl esters of 1,4 dihydropyridines as antihypertensive | TEIJIN LIMITED (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0159040-A2 | Pyridine derivatives and production thereof | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1985-10-23 | — | — | EP | disclosed |
| US-4535073-A | VASODILATION | NIPPON SHINYAKU CO LIMITED (JP) | 1985-08-13 | — | — | US | disclosed |
| EP-0128010-A2 | 1,4-Dihydropyridine derivative, process for production thereof and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
| EP-0127150-A2 | 2,6-Disubstituted-1,4-dihydropyridine derivative, process for the preparation of the same and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-05 | — | — | EP | disclosed |
| EP-0121117-A1 | Derivatives of dihydropyridine and production thereof | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1984-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | ADH1C, PRMT1, SCN1B | SMN1; SMN2 376/4885ALDH1A1 426/4885L3MBTL1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.